Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

A comprehensive review of ischemic heart disease: pathophysiology, current treatments, natural products-based therapies, and nanotherapeutics

Saadeldeen AM., Mansour A., El-Dessouki AM., Fahim SA., Shaheen AM., Ismail RA.

Narrative Review on Cardiovascular Disease, Chronic Inflammation, published in Front Pharmacol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Pharmacol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42328626
PMCID
PMC13275444
DOI
10.3389/fphar.2026.1834343

Abstract (original English)

Ischemic heart disease (IHD) is one of the major cardiovascular disorders leading to global morbidity and mortality and represents a huge burden on individuals and the healthcare system worldwide. Classically, it is attributed to obstructive atherosclerotic plaques in the epicardial coronary arteries; however, it is now understood to be a heterogeneous disease that also includes microvascular dysfunction, vasospasm, and ischemia with non-obstructive coronary arteries (INOCA). IHD is triggered by modifiable and non-modifiable risk factors, and its diagnosis relies on clinical assessment, electrocardiography, cardiac biomarkers, and advanced imaging techniques. Extensive investigations and trials have established the management of IHD, including lifestyle modifications, pharmacological therapies, and revascularization, while novel interventional, regenerative, and molecularly targeted therapies are under active investigation. This review provides a comprehensive overview of IHD, integrating its epidemiology, risk factors, pathophysiology, diagnostics, and therapeutics. IHD pathogenesis is complex, involving coronary atherosclerosis, plaque disruption, thrombosis, and myocardial ischemia-reperfusion injury that are modulated by oxidative stress, inflammation, and other signaling pathways. The review also addresses the molecular mechanisms and therapeutic potential of natural bioac

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research